NVDA
NVIDIA
-- 132.000 TSLA
Tesla
-- 463.020 AVGO
Broadcom
-- 250.000 PLTR
Palantir
-- 75.750 MSTR
MicroStrategy
-- 408.500 
NEWS
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascular health markers.
In the trial of 94 subjects, pemvidutide reduced liver fat content by up to 68.5%, total cholesterol by 12.2%, and triglycerides by 44.6% after 12 weeks.
The company is currently conducting the Phase 2b IMPACT trial in MASH patients, with results expected in Q2 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
TheReason : thank you